Print

IMPAACT P1112

Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) April 01, 2015
VRC-HIVMAB060-00-AB VRC01 Antibody
VRC-HIVMAB060-00-AB Passive Immunization
USA, Puerto Rico, South Africa 78
NCT02256631
https://clinicaltrials.gov/show/NCT02256631